THRIVE is a competitive seed grant program designed to support research that helps to predict, reduce, or prevent adverse events associated with life-saving cancer therapy. We are pleased to announce this year’s grant award winners, selected from a large pool of highly competitive proposals received from research around the globe. Each awardee , listed below, will receive $45,000 in funding to support their research in making cancer patient quality of life an active research priority.
2022 THRIVE Grant Award Winners
HESI THRIVE Research Study: Bispecific SNIPER Antibody to Reduce Off-Target Toxicities for Neuroblastoma Tumors
- Dr. Amy Erbe Gurel , BS/PhD,
- University of Wisconsin-Madison
HESI THRIVE Research Study: Breath Biomarkers for Early Diagnosis and Prediction of the Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor–Modified T-cell Therapy
- Dr. Teny John, MBBS/MD,
- University of Texas, MD Anderson Cancer Center
HESI THRIVE Research Study: Minimizing Immune checkpoint Inhibitor associated Myocarditis
- Dr. Chunru Lin, MD/PhD,
- University of Texas, MD Anderson Cancer Center
HESI THRIVE Research Study: Redox-active drug, BMX-001, as a neuroprotectant: A preventive strategy for chemotherapy induced neurotoxicity
- Dr. Angeles Alvarez Secord MD/MHSc
- Duke University
By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities. Click here to learn more about grant guidelines, the application process, and selection process.